Enliven Therapeutics Inc.
ELVN | NASDAQ
$48.87
-$0.58 (-1.17%)
At close: Sep 21, 2026, 4:00 PM ET
$48.75
-$0.12 (-0.25%)
Pre-market:
Sep 22, 2026, 8:10 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 263K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -263K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -119.66M | -104.55M | -83.53M | -38.79M | -24.76M | -9.32M |
Interest Income | 16.01M | 14.89M | 11.97M | 1.13M | 22K | 483K |
Pretax Income | -103.69M | -88.79M | -71.58M | -37.66M | -24.74M | -18.97M |
Net Income | -103.69M | -89.02M | -71.58M | -37.66M | -24.74M | -18.97M |
Selling & General & Admin | 33.8M | 23.78M | 18.96M | 7.77M | 4.29M | 1.08M |
Research & Development | 85.86M | 80.78M | 64.57M | 31.02M | 20.47M | 8.24M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 119.4M | 104.55M | 83.53M | 38.79M | 24.76M | 9.32M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 119.66M | 104.55M | 83.53M | 38.79M | 24.76M | 9.32M |
Income Tax Expense | n/a | 232K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 56.66M | 47.07M | 35.55M | 6.25M | 7.81M | 4.39M |
Shares Outstanding (Diluted) | 56.66M | 47.07M | 35.55M | 6.25M | 7.82M | 4.39M |
EPS (Basic) | -1.83 | -1.89 | -2.01 | -6.03 | -3.17 | -4.31 |
EPS (Diluted) | -1.83 | -1.89 | -2.01 | -6.03 | -3.17 | -4.31 |
EBITDA | -103.43M | -88.48M | -71.29M | -37.45M | -24.63M | -9.27M |
EBIT | -103.69M | -88.79M | -71.58M | -37.66M | -24.74M | -9.32M |
Depreciation & Amortization | 263K | 317K | 297K | 215K | 115K | 45K |
Add to Watchlist
Select watchlists to add or remove ELVN